AdaptHealth's $490M-$520M EBITDA Target Is the Real Test After the $235M Divestiture

The 2026 target is plausible, but investors are still weighing execution trust more than the headline numbers

This is a trust trade now, not just a guidance trade.

AdaptHealth has put a workable 2026 case on the table: $2.85 billion to $2.89 billion in revenue and $490 million to $520 million in adjusted EBITDA from continuing operations. But the market is not judging the company from a clean slate. It is still looking through the last quarter: $740.3 million in revenue, $132.0 million in adjusted EBITDA, and a $145.3 million net loss driven largely by a $144.2 million goodwill impairment. That matters because recent disappointments tend to set the baseline for how aggressively new numbers get tested.

The bull case is straightforward. The sale of Diabetes Health for $235.0 million in cash is the cleanup move that could help investors separate one disrupted period from the earnings power of a narrower business. The bear case is that, after a loss of that size, one better quarter may not be enough. That is why the real question now is not whether the target looks good on paper, but whether the market starts to believe the operating reset is sticking.

Q2 pressure came from timing and mix, not from weak growth

The core issue in Q2 was not demand. It was the lag between revenue growth and margin recovery. AdaptHealth still posted $740.3 million in revenue and 15.9% organic revenue growth, but adjusted EBITDA came in at $132.0 million, or 17.8% margin. That is why investors are focused less on whether the company is scaling and more on whether it can convert that scale into more consistent earnings.

Why capitated transitions can press margins first

The issue is easier to understand when you look at the mechanism. As AdaptHealth expands into risk-based contracts, volume and member growth can still show up quickly. But margin then depends on utilization management, supply routing, adherence, and other cost controls. That means a scaling phase can create a temporary gap between revenue growth and profitability even if the model is not structurally broken.

Management tied that pressure to the West Coast capitated transition and a manufacturer price increase, while also noting that the Diabetes Health business is being segregated. That does not make the EBITDA target automatic, but it does make the next few quarters a clearer test of whether this was a learning-curve problem or something more durable.

What would make the $490M-$520M EBITDA range credible

For the forward EBITda range to earn more trust, investors should look for evidence that management is learning from the Q2 mix of challenges rather than simply recharacterizing them.

• No second major execution shock. If another capitated scale-in collides with unfavorable pricing or input-cost movement, investors are more likely to see a structural margin problem.
• More normalized operating marks from the West Coast contract. As the transition matures, the company should be able to show steadier conversion of growth into earnings.
• Better visibility into the cleaned-up portfolio. With Diabetes Health moving to discontinued operations, future results should reflect a more focused set of businesses.

If those conditions start to appear, the market may be more willing to separate implementation friction from a broken model. If they do not, policy and sentiment will remain easy fallback explanations for a continuing valuation discount.

Medicare enforcement is an ecosystem overhang, even if it does not directly target AdaptHealth

Even if execution improves, the stock may still be discounted because Washington remains hostile to home-based care reimbursement. In May, CMS implemented a six-month nationwide moratorium on new Medicare enrollment for hospice and home health agencies, and that moratorium may be extended in six-month increments. That action does not directly govern DMEPOS in the same way, but it does signal that home-based care categories are under heightened scrutiny.

Why regulatory mood can affect valuation beyond the rule itself

The market often reacts to the category, not just the company. When policymakers focus on fraud in a care setting, investors can start underwriting the whole segment more cautiously. CMS has also said it will intensify investigations, use more data analytics, and remove problematic providers more quickly. Even a public company that is operating cleanly can feel that pressure if it leads investors to demand a higher risk premium for the group.

The reset only works if the next few quarters reinforce each other

The Diabetes Health sale for $235.0 million in cash matters because it removes a distraction and gives management a cleaner stage. But after the goodwill impairment-led reset, one clean quarter is unlikely to settle the debate. Investors still need evidence that operating discipline is holding across quarters.

What would support the reset

• Repeatable execution: another quarter showing that the portfolio cleanup is narrowing risk and stabilizing operations, not just changing the story around the numbers.
• A more normalized contract transition: signs that the first full quarter under the exclusive capitated agreement and the Humana-related transition are becoming more routine.
• Margin control as scale continues: evidence that the company can absorb contract transitions and input-cost pressure without another sharp margin slip.

What would weaken the case

• A clean look only because discontinued items were segregated, while core operations still struggle when growth or risk-based contracts expand.
• More pressure from policy and market psychology, especially if the moratorium environment may be extended in six-month increments and investors keep applying a credibility discount to the stock.

That is why the next few quarters matter so much. In a credibility trade, durable proof gets priced quickly, and repeatable slippage gets punished even faster.